← Back to Search

Angiotensin II Receptor Blocker

Losartan for Cystic Fibrosis

Phase 2
Recruiting
Led By Charles Bengtson, MD, MSc
Research Sponsored by University of Kansas Medical Center
Eligibility Criteria Checklist
Specific guidelines that determine who can or cannot participate in a clinical trial
Must have
Timeline
Screening 3 weeks
Treatment Varies
Follow Up baseline through week 12

Summary

This trial aims to see if using losartan in people with cystic fibrosis who are already on modulator therapy can improve the response of a specific channel in the body. Participants will take either

Who is the study for?
This trial is for individuals with cystic fibrosis who are currently receiving modulator therapy. Specific eligibility details aren't provided, but typically participants must meet certain health criteria and not have conditions that would exclude them from safely participating.
What is being tested?
The study is testing whether losartan can improve the effectiveness of modulator therapy in cystic fibrosis patients by measuring changes in sweat chloride levels over twelve weeks. Participants will be randomly assigned to receive either losartan or a placebo.
What are the potential side effects?
While specific side effects are not listed, common side effects of losartan may include dizziness due to low blood pressure, increased potassium levels, kidney function changes, and allergic reactions.

Timeline

Screening ~ 3 weeks
Treatment ~ Varies
Follow Up ~baseline through week 12
This trial's timeline: 3 weeks for screening, Varies for treatment, and baseline through week 12 for reporting.

Treatment Details

Study Objectives

Study objectives can provide a clearer picture of what you can expect from a treatment.
Primary study objectives
Sweat chloride
Secondary study objectives
Adverse events
CFQ-R
Inflammatory mediators - airway
+5 more

Side effects data

From 2021 Phase 4 trial • 227 Patients • NCT02188121
43%
Laboratory values outside normal range
23%
Psychiatric Hospitalization
6%
Medical Hospitalization
2%
Elevated creatine kinase level
1%
Muscle pain
1%
Hypotension
1%
Dehydration
1%
Leukemia
1%
Placed on Lithium while on Losartan
100%
80%
60%
40%
20%
0%
Study treatment Arm
Statin and/or Angiotensin Receptor Blocker
Usual Treatment

Trial Design

2Treatment groups
Experimental Treatment
Placebo Group
Group I: LosartanExperimental Treatment1 Intervention
Losartan 25mg twice daily for one week followed by 50mg twice daily through week 12.
Group II: PlaceboPlacebo Group1 Intervention
Placebo twice daily through week 12
Treatment
First Studied
Drug Approval Stage
How many patients have taken this drug
Losartan
2003
Completed Phase 4
~3000

Find a Location

Who is running the clinical trial?

University of Kansas Medical CenterLead Sponsor
510 Previous Clinical Trials
176,841 Total Patients Enrolled
10 Trials studying Cystic Fibrosis
432 Patients Enrolled for Cystic Fibrosis
Charles Bengtson, MD, MScPrincipal InvestigatorUniversity of Kansas Medical Center
~28 spots leftby May 2027
Unbiased ResultsWe believe in providing patients with all the options.
Your Data Stays Your DataWe only share your information with the clinical trials you're trying to access.
Verified Trials OnlyAll of our trials are run by licensed doctors, researchers, and healthcare companies.
Back to top